Review article · 2026 · Open access
cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges
Cytotherapy, 28(10), 102815 · Published 4 April 2026 · DOI 10.1016/j.jcyt.2026.102815
In brief
“cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges” is a 2026 review article by Xiangliang Lin and Thi Van Anh Bui, published in Cytotherapy. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Cytotherapy.
- Citations
- 0
- References
- 143
- Authors
- 2
Abstract
Induced pluripotent stem cells (iPSCs), which can be applied to disease modeling, regenerative medicine, and cultivated meat, among other uses, have opened a new era in the biomedical field. To obtain sufficient high-quality cells for these applications, a current good manufacturing practice (cGMP)-compliant large-scale expansion is necessary. It indicates that the entire process for producing iPSCs should adhere to cGMP regulations, encompassing both upstream steps, such as raw material collection, reprogramming, and large-scale expansion, as well as downstream steps, including harvesting, concentrating, and cryopreserving the cells. Importantly, well-established critical quality attributes are mandatory to ensure the quality of the produced cells. For decades, huge efforts have been made to initiate and develop each step of the process. However, there are still limitations and obstacles that slow down the progress of the cGMP large-scale production of iPSC. Therefore, in this review, we summarize the accomplishments and challenges of current technologies involved in making applicable and clinical iPSCs. Throughout this, future directions and solutions can be suggested for the production of large-scale, high-quality iPSCs.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Lin, X., & Bui, T. V. A. (2026). cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges. Cytotherapy, 28(10), 102815. https://doi.org/10.1016/j.jcyt.2026.102815
MLA 9
Lin, Xiangliang, and Thi Van Anh Bui. “cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges.” Cytotherapy, vol. 28, no. 10, 2026, p. 102815. https://doi.org/10.1016/j.jcyt.2026.102815.
Chicago
Lin, Xiangliang and Thi Van Anh Bui. 2026. “cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges.” Cytotherapy 28 (10): 102815. https://doi.org/10.1016/j.jcyt.2026.102815.
Harvard
Lin, X. and Bui, T. V. A. (2026) ‘cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges’, Cytotherapy, 28(10), p. 102815. doi:10.1016/j.jcyt.2026.102815.
IEEE
X. Lin and T. V. A. Bui, “cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges,” Cytotherapy, vol. 28, no. 10, p. 102815, 2026, doi: 10.1016/j.jcyt.2026.102815.
BibTeX
@article{lin2026cgmp,
title = {{cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges}},
author = {Lin, Xiangliang and Bui, Thi Van Anh},
journal = {Cytotherapy},
year = {2026},
volume = {28},
number = {10},
pages = {102815},
doi = {10.1016/j.jcyt.2026.102815},
url = {https://doi.org/10.1016/j.jcyt.2026.102815}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- induced pluripotent stem cells
- cyclic GMP
- large-scale cell expansion
- critical quality attributes
- cellular reprogramming
- cell cryopreservation
- cell harvesting
- disease modeling
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Lin, X., & Bui, T. V. A. (2026). cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges. Cytotherapy, 28(10), 102815. https://doi.org/10.1016/j.jcyt.2026.102815
How many times has this paper been cited?
0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Cytotherapy: sign in and open the full text from this page.
Who wrote this paper?
Xiangliang Lin, Thi Van Anh Bui.
What is the DOI of this paper?
10.1016/j.jcyt.2026.102815, permanently at https://doi.org/10.1016/j.jcyt.2026.102815. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.